An overview of rosuvastatin/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia
- 8 February 2020
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 21 (5) , 531-539
Abstract
Introduction: Although statin therapy is a powerful lipid-lowering strategy, only one-fifth of statin users currently reach their lipid goals. In addition, statin treatment alone has relatively low efficacy in reducing other lipid fractions than low-density lipoprotein-cholesterol (LDL-C). In such cases, most guidelines recommend adding the cholesterol absorption inhibitor ezetimibe. Areas covered: This paper summarizes the main pharmacological characteristics of rosuvastatin and ezetimibe (mechanism of action, metabolism), their lipid-lowering and pleiotropic effects, with particular attention to the clinical effects of the combined drugs in hypercholesterolemia and mixed dyslipidemia patients (such as the ones affected by diabetes mellitus and Acquired Immune Deficiency Syndrome (AIDS)). Expert opinion: The additive effect of rosuvastatin and ezetimibe helps to reach lipid goals in a large number of high-risk patients, while avoiding some safety issues related to high dosages of intensive statin therapy. Patients with diabetes receive additional benefits from ezetimibe as they seem to absorb cholesterol more effectively than non-diabetic ones, because of increased NPC1L1 gene expression. Ezetimibe augments rosuvastatin triglyceride-lowering and anti-inflammatory effects, as well. Taking into account its excellent safety profile and lack of clinically relevant drug-drug interactions, the rosuvastatin/ezetimibe association is a valuable alternative to statin dose uptitration.Keywords
Funding Information
- was not funded
This publication has 91 references indexed in Scilit:
- Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapyVascular Health and Risk Management, 2013
- Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetesLipids in Health and Disease, 2013
- Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibeLipids in Health and Disease, 2013
- Proprotein convertase subtilisin/kexin type 9 (PCSK9): From structure–function relation to therapeutic inhibitionNutrition, Metabolism and Cardiovascular Diseases, 2011
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinNew England Journal of Medicine, 2008
- Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIVLipids in Health and Disease, 2007
- Risk Assessment Chart for Death From Cardiovascular Disease Based on a 19-Year Follow-up Study of a Japanese Representative PopulationCirculation Journal, 2006
- Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) StudyAmerican Heart Journal, 2005
- EzetimibeClinical Pharmacokinetics, 2005
- Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemiaThe American Journal of Cardiology, 2004